60 Degrees Pharmaceuticals(US:SXTP) Globenewswire·2026-03-31 11:01Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in net product revenues and improvements in net loss for the fiscal year 2025, driven by increased sales and strategic partnerships [5][4]. Financial Highlights - FY 2025 net product revenues increased by 65% to $1.005 million, up from $607.6 thousand in 2024, attributed to rising sales, price increases, and fewer returns [5]. - Gross profit for 2025 was approximately $223.8 thousand, slightly up from $222.8 thousand in 2024, despite inventory write-offs related to short-dated products [5]. - Operating expenses decreased to approximately $8.4 million in 2025 from $10.0 million in 2024, with a notable reduction in R&D costs [5]. - Net loss attributable to common shareholders improved to approximately $7.37 million, or $11.73 per share, compared to a net loss of approximately $7.96 million, or $74.17 per share, in 2024 [5]. Recent Business Highlights - In March 2026, the company announced successful outcomes in its expanded access study for relapsing babesiosis, leading to calls for revised treatment guidelines [5]. - A partnership with GoodRx was established in February 2026 to offer savings on ARAKODA®, expanding its sales footprint to over 70,000 pharmacies [5]. - The company exercised its Florida State University license option for large-scale purification of castanospermine in January 2026, indicating readiness to begin regulatory processes for Australian Chestnut Extract [5]. - A Phase 2 B-FREE Chronic Babesiosis Study commenced in November 2025, aiming to enroll up to 100 patients [5]. - A sponsored research agreement with Tulane University was signed in July 2025 to evaluate tafenoquine's activity against Lyme and Bartonella bacteria [5].